|
Giselle Sholler, M.D. Chair, NMTRC
Co-Director, Pediatric Cancer Translational Research Program; Associate Professor, Center for Cancer Genomics and Quantitative Biology; Head, Laboratory of Neuroblastoma Translational Research - Van Andel Research Institute
Haworth Family Director of Innovative Therapeutics Clinic, Helen DeVos Children's Hospital Dr. Sholler received her M.D. from New York Medical College, in Valhalla, NY. She was a resident in pediatrics and subsequently was a fellow in pediatric hematology/oncology at Brown University, and then worked in the Division of Pediatric Hematology/Oncology at the University of Vermont. Dr. Sholler joined Van Andel Research Institute in 2011 as Co-Director of the Pediatric Oncology Program, Associate Professor in the Center for Cancer Genomics and Quantitative Biology, and Head of the Laboratory of Neuroblastoma Translational Research. She is also jointly appointed with the Helen DeVos Children's Hospital as Haworth Family Director of Innovative Therapeutics Clinic and is chair of the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). (full bio) |
| |
|
|
Jeffrey Trent, Ph.D., F.A.C.M.G. President and Research Director, Translational Genomics Research Institute (TGen) Dr. Trent is the founding President and Research Director of the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. His research has provided important insights into the genetic basis of cancer. He is the author of more than 300 manuscripts in the scientific literature, numerous book chapters, invited reviews in the scientific literature, and hundreds of invited lectures. He has received numerous honors and awards and he has sat on the editorial boards of a dozen scientific publications. He specializes in developing and integrating novel “omic” technologies, supporting studies of molecular changes related to the predisposition to, and progression of, human cancers and other complex diseases. |
| |
|
|
Barton A. Kamen, M.D., Ph.D. American Cancer Society Clinical Research Professor
Professor of Pediatrics & Pharmacology
Robert Wood Johnson Medical School (volunteer) Dr. Kamen received his M.D. and Ph.D. from Case Western Reserve University, Cleveland, OH, and served his residency and fellowship in pediatrics and pediatric hematology/oncology and pharmacology at Yale University, New Haven, CT. Dr. Kamen's current clinical and research interests are centered about folate and anti-folate metabolism, drug development, neurotoxicity from therapy, metronomic therapy for cancer and the development of novel antibodies for treating patients with cancer. (Dr. Kamen speaking at TedMed 2009) |
| |
|
|
Craig Webb, Ph.D. Co-Director, Pediatric Cancer Translational Research Program; Professor, Center for Cancer Genomics and Computational Biology; Director, Laboratory for Translational Medicine - Van Andel Research Institute Dr. Webb received his Ph.D. in cell biology from the University of East Anglia, England, in 1995. He then served as a postdoctoral fellow in the laboratory of George Vande Woude in the Molecular Oncology Section of the Advanced BioScience Laboratories–Basic Research Program at the National Cancer Institute–Frederick Cancer Research and Development Center, Maryland (1995–1999). Dr. Webb joined VARI as a Scientific Investigator in October 1999. (full bio) |
| |
|
|
André Bachmann, Ph.D. Associate Professor, Cancer Research Center of Hawaii; Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii at Manoa Dr. Bachmann received his Ph.D. in Biology and M.S. in Microbiology from the University of Zurich, Switzerland. Dr. Bachmann has been studying ODC, a protein that often is over-expressed in cancer. He has shown that this protein promotes neuroblastoma tumor growth, while a specific inhibitor of ODC called DFMO promotes cancer cell death. Bachmann's lab also is studying the molecular mechanisms of cell death in neuroblastoma, with the goal of trying to identify novel, natural product-derived drugs that inhibit these processes. (full bio) |
| |
|
| |
Jeffrey Bond, Ph.D. Research Associate Professor of Microbiology and Molecular Genetics, Vermont Cancer Center, University of Vermont Dr. Bond received his Ph.D. in biophysics from the University of Rochester, and obtained postdoctoral training at Cornell University and the University of Wisconsin-Madison. He joined the faculty of the UVM College of Medicine in 1995, and his research program focuses on genome stability and expression. (full bio) |
| |
|
|
Javed Khan, M.D. Head, Oncogenomics Section
Senior Investigator
Pediatric Oncology Branch
Center for Cancer Research
National Cancer Institute Dr. Khan obtained his bachelor's degree in 1984 and his master's degrees in 1989 in immunology and parasitology at England's University of Cambridge. He subsequently obtained his M.D. there and the postgraduate degree of MRCP (Membership of the Royal College of Physicians), equivalent to board certification in the United States. After clinical training in internal medicine and pediatrics as well as other specialties, he received a Leukemia Research Fellowship. In May 2001, Dr. Khan joined the Pediatric Branch, NCI, as a tenure track investigator. Dr. Khan and colleagues have published a new model for diagnosis of cancer using artificial neural networks (ANN), a form of artificial intelligence, and microarray technology. In April 2001, Dr. Khan was recognized by the American Association for Cancer Research for his work in tumor profiling by receiving a Scholar in Training Award. (full bio) |
| |
|
|
Jacqueline M. Kraveka, M.D. Assistant Professor of Pediatrics
College of Medicine
Medical University of South Carolina Dr. Kraveka received her M.D. from Nova Southeastern University College of Osteopathic Medicine, North Miami Beach, FL. Dr. Kraveka is actively involved in clinical pediatric research in the Children’s Oncology Group, where she is a member of the Non-Hodgkin’s Lymphoma and Neuroblastoma Committees. As the institutional COG Principal Investigator, she is responsible for the conduct of over 40 COG Phase II and Phase III trials at MUSC. In addition to clinical research, she is also very involved in translational and bench research and has the only research laboratory in South Carolina dedicated to pediatric cancer. Her research is focused on the regulation of telomerase by ceramide in human neuroblastoma differentiation and telomerase inhibition. The long-term goal of her research is to develop novel therapeutic strategies for the treatment of childhood cancer. (full bio) |
| |
|
|
Don Eslin, M.D. Center for Children's Cancer and Blood Disorders
Arnold Palmer Hospital for Children
M.D. Anderson Cancer Center Orlando Dr. Don Eslin, pediatric hematologist/oncologist, is a member of the Pediatric Hematology/Oncology Department at MD Anderson Cancer Center Orlando. He also serves as a clinical associate professor in the Department of Pediatrics at Florida State University. Dr. Eslin is certified by the American Board of Pediatrics in general pediatrics and pediatric hematology/oncology. Dr. Eslin earned his medical degree from Marshall University School of Medicine in Huntington, West Virginia, and completed a residency in pediatrics through Orlando Health's Arnold Palmer Hospital for Children. He fulfilled a fellowship in pediatric hematology/oncology at Children's Hospital of Philadelphia and held a National Research Fellowship Award from the Kennedy Krieger Institute in Baltimore. (more info) |
